FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615256918> ?p ?o ?g. }

• W2615256918 endingPage "e690S" @default.
• W2615256918 startingPage "e669S" @default.
• W2615256918 abstract "BackgroundThis guideline focuses on antithrombotic drug therapies for primary and secondary prevention of cardiovascular disease as well as for the relief of lower-extremity symptoms and critical ischemia in persons with peripheral arterial disease (PAD).MethodsThe methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement.ResultsThe most important of our 20 recommendations are as follows. In patients aged ≥ 50 years with asymptomatic PAD or asymptomatic carotid stenosis, we suggest aspirin (75-100 mg/d) over no therapy (Grade 2B) for the primary prevention of cardiovascular events. For secondary prevention of cardiovascular disease in patients with symptomatic PAD (including patients before and after peripheral arterial bypass surgery or percutaneous transluminal angioplasty), we recommend long-term aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 1A). We recommend against the use of warfarin plus aspirin in patients with symptomatic PAD (Grade 1B). For patients undergoing peripheral artery percutaneous transluminal angioplasty with stenting, we suggest single rather than dual antiplatelet therapy (Grade 2C). For patients with refractory claudication despite exercise therapy and smoking cessation, we suggest addition of cilostazol (100 mg bid) to aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 2C). In patients with critical limb ischemia and rest pain unable to undergo revascularization, we suggest the use of prostanoids (Grade 2C). In patients with acute limb ischemia due to acute thrombosis or embolism, we recommend surgery over peripheral arterial thrombolysis (Grade 1B).ConclusionsRecommendations continue to favor single antiplatelet therapy for primary and secondary prevention of cardiovascular events in most patients with asymptomatic PAD, symptomatic PAD, and asymptomatic carotid stenosis. Additional therapies for relief of limb symptoms should be considered only after exercise therapy, smoking cessation, and evaluation for peripheral artery revascularization. This guideline focuses on antithrombotic drug therapies for primary and secondary prevention of cardiovascular disease as well as for the relief of lower-extremity symptoms and critical ischemia in persons with peripheral arterial disease (PAD). The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. The most important of our 20 recommendations are as follows. In patients aged ≥ 50 years with asymptomatic PAD or asymptomatic carotid stenosis, we suggest aspirin (75-100 mg/d) over no therapy (Grade 2B) for the primary prevention of cardiovascular events. For secondary prevention of cardiovascular disease in patients with symptomatic PAD (including patients before and after peripheral arterial bypass surgery or percutaneous transluminal angioplasty), we recommend long-term aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 1A). We recommend against the use of warfarin plus aspirin in patients with symptomatic PAD (Grade 1B). For patients undergoing peripheral artery percutaneous transluminal angioplasty with stenting, we suggest single rather than dual antiplatelet therapy (Grade 2C). For patients with refractory claudication despite exercise therapy and smoking cessation, we suggest addition of cilostazol (100 mg bid) to aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 2C). In patients with critical limb ischemia and rest pain unable to undergo revascularization, we suggest the use of prostanoids (Grade 2C). In patients with acute limb ischemia due to acute thrombosis or embolism, we recommend surgery over peripheral arterial thrombolysis (Grade 1B). Recommendations continue to favor single antiplatelet therapy for primary and secondary prevention of cardiovascular events in most patients with asymptomatic PAD, symptomatic PAD, and asymptomatic carotid stenosis. Additional therapies for relief of limb symptoms should be considered only after exercise therapy, smoking cessation, and evaluation for peripheral artery revascularization." @default.
• W2615256918 created "2017-05-26" @default.
• W2615256918 creator A5002475361 @default.
• W2615256918 creator A5012215238 @default.
• W2615256918 creator A5016851305 @default.
• W2615256918 creator A5017952355 @default.
• W2615256918 creator A5021895738 @default.
• W2615256918 creator A5022702753 @default.
• W2615256918 creator A5027185327 @default.
• W2615256918 creator A5031717153 @default.
• W2615256918 creator A5041615321 @default.
• W2615256918 creator A5058205892 @default.
• W2615256918 creator A5080397161 @default.
• W2615256918 date "2012-02-01" @default.
• W2615256918 modified "2023-10-16" @default.
• W2615256918 title "Antithrombotic Therapy in Peripheral Artery Disease" @default.
• W2615256918 cites W1485191699 @default.
• W2615256918 cites W1840506659 @default.
• W2615256918 cites W1969956137 @default.
• W2615256918 cites W1974252913 @default.
• W2615256918 cites W1974487821 @default.
• W2615256918 cites W1977079423 @default.
• W2615256918 cites W1978322467 @default.
• W2615256918 cites W1980472079 @default.
• W2615256918 cites W1985658516 @default.
• W2615256918 cites W1986673853 @default.
• W2615256918 cites W1998156657 @default.
• W2615256918 cites W2019549675 @default.
• W2615256918 cites W2022839467 @default.
• W2615256918 cites W2026858493 @default.
• W2615256918 cites W2033338007 @default.
• W2615256918 cites W2033750122 @default.
• W2615256918 cites W2033847528 @default.
• W2615256918 cites W2044609151 @default.
• W2615256918 cites W2044810453 @default.
• W2615256918 cites W2046759244 @default.
• W2615256918 cites W2051208636 @default.
• W2615256918 cites W2054990351 @default.
• W2615256918 cites W2057244473 @default.
• W2615256918 cites W2058275250 @default.
• W2615256918 cites W2059885795 @default.
• W2615256918 cites W2060409665 @default.
• W2615256918 cites W2060691994 @default.
• W2615256918 cites W2062046526 @default.
• W2615256918 cites W2066582340 @default.
• W2615256918 cites W2067185349 @default.
• W2615256918 cites W2069480077 @default.
• W2615256918 cites W2070488805 @default.
• W2615256918 cites W2075318838 @default.
• W2615256918 cites W2079032946 @default.
• W2615256918 cites W2079595856 @default.
• W2615256918 cites W2083658810 @default.
• W2615256918 cites W2085793873 @default.
• W2615256918 cites W2089410119 @default.
• W2615256918 cites W2090947041 @default.
• W2615256918 cites W2096240645 @default.
• W2615256918 cites W2100089051 @default.
• W2615256918 cites W2100209149 @default.
• W2615256918 cites W2102937816 @default.
• W2615256918 cites W2105400393 @default.
• W2615256918 cites W2106889389 @default.
• W2615256918 cites W2111192628 @default.
• W2615256918 cites W2117658232 @default.
• W2615256918 cites W2117838742 @default.
• W2615256918 cites W2122891093 @default.
• W2615256918 cites W2123884912 @default.
• W2615256918 cites W2124840320 @default.
• W2615256918 cites W2133786107 @default.
• W2615256918 cites W2140247626 @default.
• W2615256918 cites W2141913785 @default.
• W2615256918 cites W2144419036 @default.
• W2615256918 cites W2144985796 @default.
• W2615256918 cites W2147800731 @default.
• W2615256918 cites W2151036184 @default.
• W2615256918 cites W2153281494 @default.
• W2615256918 cites W2154532030 @default.
• W2615256918 cites W2156668289 @default.
• W2615256918 cites W2157276089 @default.
• W2615256918 cites W2163011256 @default.
• W2615256918 cites W2163723083 @default.
• W2615256918 cites W2325910649 @default.
• W2615256918 cites W3021516239 @default.
• W2615256918 cites W4236878386 @default.
• W2615256918 cites W4246778063 @default.
• W2615256918 doi "https://doi.org/10.1378/chest.11-2307" @default.
• W2615256918 hasPublicationYear "2012" @default.
• W2615256918 type Work @default.
• W2615256918 sameAs 2615256918 @default.
• W2615256918 citedByCount "171" @default.
• W2615256918 countsByYear W26152569182012 @default.
• W2615256918 countsByYear W26152569182013 @default.
• W2615256918 countsByYear W26152569182014 @default.
• W2615256918 countsByYear W26152569182015 @default.
• W2615256918 countsByYear W26152569182016 @default.
• W2615256918 countsByYear W26152569182017 @default.
• W2615256918 countsByYear W26152569182018 @default.
• W2615256918 countsByYear W26152569182019 @default.
• W2615256918 countsByYear W26152569182020 @default.

• next